Insulin resistance refers to a decreased capacity of circulating insulin to regulate nutrient metabolism. It is associated with the development of type II diabetes, a 21st century epidemic. Recent studies reveal that agents that induce insulin resistance exploit phosphorylation-based negative feedback control mechanisms otherwise utilized by insulin itself, to uncouple the insulin receptor from its downstream effectors and thereby terminate insulin signal transduction. This article focuses on the cardinal role of Ser/Thr protein kinases, which phosphorylate insulin receptor substrates, as key players in the uncoupling of insulin signaling and the induction of an insulin resistance state.
Introduction
Insulin is a major anabolic hormone whose action is essential for the growth, development, proper function of pancreatic beta cells, and homeostasis of glucose, fat, and protein metabolism. 1 At the molecular level, insulin binding to its transmembrane receptor (IR) stimulates the intrinsic Tyr kinase activity of the receptor (IRK), which then phosphorylates selective Tyr residues of target proteins such as Shc, Gab-1/2, Cbl/CAP, APS, Dock1/2, SHP-2, and the family of insulin receptor substrate (IRS) proteins {IRS À1 to -4}. 2, 3 The Tyr-phosphorylated substrates of IR then serve as docking sites for downstream effector molecules. For example, recruitment of the proteins Grb-2 and Sos to Tyrphosphorylated Shc activates the MAP kinase cascade, while association of PI3K with the IRS proteins results in the production of phosphatidyl inositol 3,4,5 phosphate (PIP3) that activates PIP3-dependent kinase 1(PDK1) and its downstream effector kinases PKB (protein Ser/Thr kinase B, also named Akt), mTOR, p70S6 kinase, and the atypical isoforms of PKC (PKC z/l). Collectively, these kinase cascades mediate the metabolic and growth-promoting functions of insulin, such as translocation of GLUT4 glucose transporters from intracellular pools to the plasma membrane; inhibition of hepatic glucose production; stimulation of glycogen and protein synthesis; regulation of b-cell function; and initiation of specific gene transcription. 2, 3 Insulin resistance is a common pathological state in which target cells fail to respond to ordinary levels of circulating insulin. 4 Individuals with insulin resistance are predisposed to developing type II diabetes, and insulin resistance is frequently associated with a number of other health disorders including obesity, hypertension, chronic infection, and cardiovascular diseases. 4 Recent studies from our laboratory have focused on Ser/Thr phosphorylation of the IRS proteins as a key negative feedback control mechanism that uncouples the IRS proteins from their upstream and downstream effectors, and terminates signal transduction in response to insulin, under physiological conditions. Emerging data further suggest that agents such as tumor necrosis factor a (TNFa), free fatty acids (FFA), and cellular stress, which inhibit insulin signaling and induce insulin resistance, take advantage of this mechanism by activating Ser/Thr kinases that phosphorylate the IRS proteins and inhibit their function. Thus, while the underlying molecular pathophysiology of insulin resistance is still not well understood, Ser phosphorylation of IRS proteins represents an important new mechanistic theme 2 that should be considered along with other potential mechanisms for the induction of insulin resistance such as increased activity of lipid-or protein-Tyr phosphatases (PTPs). 4 Ser phosphorylation as a feedback regulatory mechanism of insulin signaling 6 or Ser/Thr phosphorylation.
The latter is an attractive regulatory mechanism because it enables multilevel control of the IRS kinases activity, and of the specific targets among nearly 100 potential Ser/Thrphosphorylation sites in IRS proteins that might play regulatory roles during the insulin response ( Figure 1 ). It is becoming apparent that Ser/Thr phosphorylation of IRS proteins has a dual function, serving either a positive or a negative modulatory role in insulin signaling. Phosphorylation of Ser residues within the P-Tyr-binding (PTB) domain of IRS-1, by insulin-stimulated PKB, protects IRS proteins from the rapid action of PTPs, and enables the IRS proteins to maintain their Tyr-phosphorylated active conformation, thus implicating PKB as a positive regulator of IRS-1 functions. 7 12 The different biological outcomes that result due to Ser/Thr phosphorylation of IRS proteins raise the question as to which insulin-stimulated kinase mediates each function, and which Ser sites are getting phosphorylated.
We have demonstrated that the activity of the insulinstimulated inhibitory kinases is blocked by inhibitors of the PI3K pathway, implicating PI3K itself, or downstream effectors of PI3K, as negative regulators of IRS protein function. 7, 9 A potential candidate is the mammalian target of rapamycin (mTOR), which enhances phosphorylation of Ser residues at the COOH terminus of IRS-1. This phosphorylation inhibits insulin-stimulated Tyr phosphorylation of IRS-1 and its ability to bind PI3K. 13 Studies by us and by others provided evidence that PKCz, which is activated by insulin, 14 mediates phosphorylation of IRS proteins. 9, 15 This leads to the dissociation of the IR-IRS complexes, 9 inhibits the ability of IRS proteins to undergo insulin-stimulated Tyr phosphorylation, and terminates insulin signaling. IRS-1 serves as a substrate for PKCz in vitro, and endogenous IRS-1 forms complexes with PKCz in an insulin-dependent manner. 15 These findings suggest that PKCz can function as an insulin-stimulated IRS kinase, although downstream effectors of PKCz could also fulfill this role. A potential candidate is the IkB kinase b (IKKb). IKKb binds PKCz both in vitro and in vivo, serves as an in vitro substrate for PKCz, and is activated by a functional PKCz. 16 Furthermore, recent evidence indicates that IKKb can be activated in an insulindependent manner. 17 PKB, mTOR, and PKCz are downstream effectors of PI3K along the insulin signaling pathway. This suggests that their action should be orchestrated to allow phosphorylation by PKB and sustained activation of IRS-1, prior to the activation of mTOR or PKCz, the actions of which are expected to terminate insulin signal transduction. Of note, the negative feedback control mechanism induced by PKCz (or mTOR) includes a self-attenuation mode, whereby PI3K-mediated activation of PKCz inhibits IRS-1 function; reduces complex formation between IRS-1 and PI3K, and thereby inhibits further activation of PKCz itself. 2, 9 Other aspects of insulin signaling are also subjected to homologous desensitization. Chronic stimulation with insulin results in persistent phosphorylation of the GDP-GTP exchange factor mSOS, which keeps it dissociated from the adaptor Grb2 and allows the GTPase Ras to return to its GDPbound, inactive phase. This process is apparently mediated by MAPK that phosphorylates mSOS. 18 Hence, two major insulin signaling pathways, mediated by IRS proteins and Shc, are subjected to homologous desensitization in the form of insulin-induced Ser/Thr phosphorylation. 
Ser/Thr phosphorylation of IRS proteins and insulin resistance
A major role of the induction of insulin resistance is attributed to agents such as phorbol esters, and TNFa, whose common feature is their ability to enhance Ser/Thr phosphorylation and inhibit insulin-stimulated Tyr phosphorylation of IRS proteins. 19 Since Ser/Thr phosphorylation of IRS proteins is stimulated by insulin treatment and by inducers of insulin resistance, it is of interest to determine whether the same kinases and signaling pathways are being activated under both physiological and pathological conditions. Recent studies implicate several Ser/Thr kinases as potential candidates that could fulfill this role.
PKCf and IKKb
It is now becoming apparent that insulin and agents that induce insulin resistance, such as TNFa, might stimulate the same IRS kinases. This conclusion is based, for example, upon the fact that TNFa activates PKCz and its downstream target IKKb. 16 Potential mechanisms could involve TNFa-mediated activation of sphingomyelinase and production of ceramide, which stimulates PKCz activity. 20 Indeed, the inhibitory effects of TNFa on insulin-stimulated Tyr phosphorylation of IRS proteins are mimicked by sphingomyelinase and ceramide analogs. 8, 21 This suggests that TNFa triggers a ceramideactivated kinase such as PKCz 20 to induce phosphorylation of IRS proteins. Alternatively, TNFa can induce complex formation between PKCz, p62, and RIP proteins that serve as adaptors of the TNF receptor and link PKCz to TNFa signaling. IKKb is a Ser kinase whose major substrate is the NFkB inhibitor IkB. IKKb is a downstream target of PKCz and has been recently implicated as a potential IRS kinase. The activation or overexpression of IKKb attenuated insulin signaling, whereas IKKb inhibition by high doses of salicylates or by a reduction in IKKb gene dose, reversed obesityand diet-induced insulin resistance, 22 implicating IKKb as a potential mediator of insulin resistance. Support for this conclusion is provided by the fact that insulin-sensitizing drugs, such as thiazolidinediones, inhibit NF-kB activity, whereas adiponectin, whose plasma levels are negatively correlated with insulin resistance, inhibits IKK activity. The mechanism by which lipids might activate IKKb presumably involves an increase in FFA-derived metabolites, such as diacylglycerol and ceramide, which are potent activators of PKCy 23 and PKCz, 20 both known to activate IKKb.
At the molecular level, inhibition of IKKb prevented Ser/Thr phosphorylation of IRS proteins induced by a high-fat diet, TNFa, or phosphatase inhibitors, whereas it improved insulinstimulated Tyr phosphorylation of IRS proteins, indicating that IKKb or its downstream effectors serve as IRS kinases. These findings suggest that IKKb can negatively regulate the activity of IRS proteins, making it a target for insulin sensitization. This concept was further validated in a recent study demonstrating that IRS-1 is a direct substrate for IKKb, which phosphorylates IRS-1 at Ser 307 (and other sites). 17 We c-Jun NH 2 -terminal kinase (JNK) JNK is a member of the MAP kinase family of protein kinases that also includes ERK and p38. JNK is activated by proinflammatory cytokines such as TNFa, various growth factors, as well as by insulin that stimulates JNK activity by an as yet unknown mechanism. 24 Recent studies have shown that JNK associates with IRS-1 and phosphorylates it at Ser307. Since Ser307 is adjacent to the PTB domain of IRS-1, its phosphorylation might disrupt the interaction between the juxtamembrane domain of the IR and the PTB domain IRS-1, inhibit insulin-stimulated Tyr-phosphorylation of IRS-1, and promote insulin resistance. 25 Conversely, reduced Ser 307 phosphorylation is directly related to increased insulinstimulated Tyr phosphorylation and glucose uptake. Both insulin and TNFa were shown to mediate phosphorylation of IRS-1 at Ser307, although different signaling pathways might be involved. In 3T3-L1 fibroblasts, insulin stimulates phosphorylation of Ser307 by kinases downstream of PI3K, whereas TNFa effects are mediated by members of the MAPK cascade. 25 Interestingly, JNK does not serve as an insulin-or TNFa-stimulated IRS kinase in 3T3-L1 fibroblasts, because its activity is insensitive to inhibitors that block phosphorylation of Ser307 in response to these stimuli. 25 In contrast, JNK appears to phosphorylate Ser307 in an insulin-dependent manner in 3T3-L1 adipocytes and other cells. 26 Insulin stimulation of JNK activity requires PI3K and Grb2 signaling. Direct binding of JNK to IRS-1 is not required for JNK activation by insulin; however, direct interactions between JNK and IRS-1, which has a JNK-binding motif, 27 Since each of the potential IRS kinases has a unique substrate specificity, the question remains of which Ser sites are being modified by each kinase, and what are the consequences of such phosphorylation. Present studies indicate that negative regulatory sites are found both in close proximity to the PTB domain (eg Ser307) and at the Cterminal end of IRS-1 (eg Ser612), and it still remains to be determined whether phosphorylation of Ser residues distributed along the IRS molecule contributes to a given functional change (eg enhanced dissociation of IR/IRS complexes) or whether phosphorylation of Ser residues clustered within a confined region results in a unique functional consequence. Another question still unresolved is whether the same or different signaling pathways are being utilized by insulin or agents that induce resistance to regulate the activity of IRS kinases. While the same kinases (PKCz, JNK, IKKb) can be activated by insulin, FFA, and TNFa, there is no evidence that these kinases are being activated along the same pathways. Indeed, at least under certain circumstances, kinases localized along different pathways are activated by insulin and TNFa to induce phosphorylation of the inhibitory Ser307 site. Given the large number of stimuli, pathways, kinases, and potential sites involved, it appears that Ser/Thr phosphorylation of IRS proteins represents a combinatorial consequence of several kinases, activated by different pathways, acting in concert to phosphorylate multiple sites. Still, in spite of the complexity and dynamic nature of the system, unraveling IRS kinases and their biological role is expected to provide a novel viewpoint of the molecular basis for insulin resistance. This should enable a rational drug design to inhibit selectively the activity of relevant kinases and generate a novel class of therapeutic agents for treatment of insulin resistance and type II diabetes.
